Comparative Pharmacology
Head-to-head clinical analysis: LUTREPULSE KIT versus SUPPRELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUTREPULSE KIT versus SUPPRELIN.
LUTREPULSE KIT vs SUPPRELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUTREPULSE (gonadorelin acetate) is a synthetic decapeptide analog of endogenous gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on the anterior pituitary gonadotroph cells, stimulating synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In males, LH stimulates Leydig cells to produce testosterone; in females, LH triggers ovulation and FSH stimulates follicular development.
Synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH) that acts as a potent inhibitor of gonadotropin secretion. Initially stimulates, then suppresses pituitary gonadotropin release (LH and FSH), leading to decreased testosterone and estrogen production.
5 mcg subcutaneously every 90 minutes via pulsatile pump.
50 mcg subcutaneously once daily for the first month, then 25 mcg subcutaneously once daily for maintenance. Alternatively, 7.5 mg intramuscularly once monthly.
None Documented
None Documented
3 hours (initial phase), terminal elimination half-life 10-12 hours; clinically, steady-state reached within 2 days.
Terminal elimination half-life is approximately 4-6 hours following subcutaneous administration; this supports once-daily dosing.
Renal: 10% unchanged; hepatic metabolism, metabolites primarily excreted in bile (70%) and feces.
Primarily renal, with approximately 70-80% of histrelin excreted unchanged in urine; biliary/fecal excretion accounts for about 20-30%.
Category C
Category C
GnRH Agonist
GnRH Agonist